Overview and Scope
Small cell lung cancer (SCLC) is a type of lung cancer that primarily originates in the bronchi, the airways of the lungs. Small-cell Lung cancer therapeutics provide various medical approaches, treatments and interventions to manage and treat small-cell lung cancer. It often involves a combination of different treatment modalities to achieve the best possible outcomes.
Sizing and Forecast
The small cell lung cancer therapeutics market size has grown rapidly in recent years. It will grow from $5.78 billion in 2023 to $6.62 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing prevalence of small cell lung cancer, growing awareness about small cell lung cancer, growing demand for effective and convenient treatments, government initiatives.
The small cell lung cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $10.87 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to investments in research and development activities for small cell lung cancer treatments, rising toboco smoking, growing chemotherapy, increasing healthcare expenditure. Major trends in the forecast period include advances in early detection and screening methods, clinical trial expansion, advances in radiation therapy, immunotherapy advancements.
To access more details regarding this report, visit the link:
Segmentation & Regional Insights
The small cell lung cancer therapeutics market covered in this report is segmented –
1) By Drug Type: Atezolizumab; Topotecan; Lurbinectedin; Durvalumab; Methotrexate; Pembrolizumab
2) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administrations
4) By End-Users: Hospitals; Cancer Therapy Centers; Other End-Users
North America was the largest region in the small cell Lung cancer therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in small cell lung cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12912&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of lung cancer is expected to propel the growth of the small-cell lung cancer therapeutics market going forward. Lung cancer is a malignant disease with symptoms such as coughing, chest pain and difficulty breathing that is defined by the unchecked proliferation of abnormal cells in the lung tissues. Treatment for lung cancer, including small cell lung cancer, usually involves a combination of chemotherapy, radiation therapy and, in some cases, targeted therapies that provide prolonged survival and improved quality of life for lung cancer patients. For instance, in January 2023, according to the American Cancer Society, a US-based government organization, there were approximately 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and reportedly 127,070 deaths from lung cancer (67,160 in men and 59,910 in women) in 2022. Therefore, the rise in the prevalence of lung cancer is driving the growth of the small-cell lung cancer therapeutics market.
Key Industry Players
Major players in the small cell lung cancer therapeutics market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals, Novartis AG, Merck and Co. Inc., Sanofi S.A, Bristol-Myers Squibb Company, Astrazeneca PLC, GSK PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Vertex Pharmaceuticals, Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd.
The small cell lung cancer therapeutics market report table of contents includes:
1. Executive Summary
2. Small Cell Lung Cancer Therapeutics Market Characteristics
3. Small Cell Lung Cancer Therapeutics Market Trends And Strategies
4.Small Cell Lung Cancer Therapeutics market analysis
5. Small Cell Lung Cancer Therapeutics Market Size And Growth
6. Small Cell Lung Cancer Therapeutics Segmentation
7. Small Cell Lung Cancer Therapeutics Regional And Country Analysis
.
.
.
27.Small Cell Lung Cancer Therapeutics Competitive Landscape And Company Profiles
28.Small Cell Lung Cancer Therapeutics Key Mergers And Acquisitions
29. Small Cell Lung Cancer Therapeutics Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Pfizer Inc.
- Johnson and Johnson Private Limited
- F. Hoffmann-La Roche AG
- AbbVie Inc.
- Bayer AG
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
